Summary
Fifty-seven patients with metastatic breast carcinoma have been treated with mitomycin C (10 mg/m2 IV 6-weekly), melphalan (6 mg/m2 POx3 days, 3-weekly), and methotrexate (35 mg/m2 IV 3-weekly) to assess the efficacy and toxicity of this regimen. Of 48 evaluable patients 19 (40%) responded for a median period of 5 months and 12 (25%) had stabilisation of disease. Of the 12 patients previously treated with adriamycin only one responded, whereas 18 of the 36 patients without previous chemotherapy responded. Although healing of bone metastases was infrequent control of hypercalcaemia was commonly seen. Generally the treatment was well tolerated and treatment was stopped in only five patients because of toxicity. Cummulative marrow toxicity was observed but was not a significant problem in the first 6 months of treatment. Mitomycin C, melphalan, and methotrexate (MMM) appears to provide an effective, well tolerated chemotherapy combination for metastatic breast carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Carter SK (1976) Integration of chemotherapy into combined modality treatment of solid tumours. VII. Adenocarcinoma of the breast. Cancer Treat Rev 3:141–174
Creech RH, Catalano RB, Shah MK (et al.) (1983) An effective low-dose mitomycin regimen for hormonal-and chemotherapy-refractory patients with metastatic breast cancer. Cancer 51:1034–1040
Crooke ST, Bradner WT (1976) Mitomycin C: a review. Cancer Treat Rev 3:121–139
Hayward JL, Rubens RD, Carbone PP et al. (1977) Assessment of response to therapy in advanced breast cancer. Br J Cancer 35:292–298
Konits PH, Aisner J, Van Echo DA et al. (1981) Mitomycin C and vinblastine chemotherapy for advanced breast cancer. Cancer 48:1295–1298
Mattsson W, Van Eyben F, Hallsten L et al. (1982) A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer. Cancer 49:217–220
Powles TJ, Coombes RC, Smith IE et al. (1980) Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet 1:580–582
Rowland-Payne CME, Abbott M, James JM et al. (1982) Weight loss during therapy for advanced breast cancer. Clin Oncol 8:33–38
Van Oosterom AT, Powles TJ, Hamersma E et al. (1980) A phase II study of mitomycin C in refractory advanced breast cancer. A multi-centre pilot study. Eur J Cancer Clin Oncol [Suppl] 1:275–276
Veronesi A, Tirelli Y, Galligioni E et al. (1982) Third-line chemotherapy with mitomycin, vinblastine and carmustine (BCNU) in refractory breast carcinoma: a pilot study. Cancer Treat Rep 66:559–561
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Perez, D.J., Powles, T.J., Gazet, J.C. et al. Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer. Cancer Chemother. Pharmacol. 13, 36–38 (1984). https://doi.org/10.1007/BF00401444
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00401444